BD has obtained valuable rights through the proper and continuous use of our trademarks. We adhere to the following usage guidelines to maintain the integrity of our brands and preserve their value.
Please read this Agreement carefully. By accessing or using this Site, you agree without restriction to be bound by this Agreement. If you do not agree to follow and be bound by this Agreement, you may not access, use or download materials from this Site.
This Privacy Notice describes the privacy practices of Becton, Dickinson and Company and its subsidiaries (collectively " BD”) in connection with the Surgi-Pal mobile application (the “App”).
The Site is offered in the USA only, is directed at US residents only and is governed by laws in the United States only. By accessing or using this Site, you agree without restriction to be bound by the most recent version of this Privacy Statement.
New ingredient disclosure regulations will go into effect in the State of California beginning on January 1st, 2020. These regulations, defined under the California SB-258 Cleaning Product Right to Know Act of 2017 (aka ‘SB 258’), will require website disclosure and links to specific disclosures.
BD paga a los proveedores por las compras autorizadas de acuerdo con los términos y condiciones acordados y en base a facturas debidamente constituidas. Los términos de pago se calcularán a partir de la última fecha en que se reciba una factura correcta a través de un método de envío aprobado o la recepción de bienes/servicios conformes.
BD s’acquitte du paiement auprès des fournisseurs pour les achats autorisés, conformément aux factures reçues, si elles respectent les termes et les conditions établies. Les termes de paiement sont calculés à partir de la date à laquelle la facture est reçue, si elle est conforme et que la marchandise est réceptionnée.
The Norwegian Transparency Act requires Becton Dickinson Norway AS (BD Norway) to publish an annual human rights statement on the company's human rights due diligence. The following describes the company’s effort in this regard.
The BD products listed below may be covered by one or more of the identified patents. These lists
are provided to satisfy the virtual marking provisions of the America Invents Act (35 USC 287). The
content of these lists and association between products and patents may change due to events
including, but not limited to: filing, publication, issuance, licensing, product changes, expiration,
abandonment, and other circumstances.
The BD products listed below may be covered by one or more of the identified patents. These lists are provided to satisfy the virtual marking provisions of the America Invents Act (35 USC 287). The content of these lists and association between products and patents may change due to events including, but not limited to: filing, publication, issuance, licensing, product changes, expiration, abandonment, and other circumstances.
The BD products listed below may be covered by one or more of the identified patents. These lists are provided to satisfy the virtual marking provisions of the America Invents Act (35 USC 287). The content of these lists and association between products and patents may change due to events including, but not limited to: filing, publication, issuance, licensing, product changes, expiration,
abandonment, and other circumstances
The UK Modern Slavery Act of 2015 requires certain organizations carrying out business in the United Kingdom to publish a statement regarding human trafficking and modern slavery. The following describes BD's efforts in this regard.
The California Transparency in Supply Chains Act requires BD to disclose the extent of our anti-trafficking and anti-slavery human rights efforts in our direct product supply chain in five areas: verification, audits, certification, internal accountability, and training.
Enhance medication availability while increasing security and control of medications and supplies with a comprehensive system of automated dispensing solutions and pharmacy technologies across your healthcare system.
BD is committed to staying at the forefront of developing cutting-edge venous technologies to address the unique challenges of the venous anatomy and disease states.
